Supernus Pharmaceuticals (SUPN Quick QuoteSUPN - Free Report) reported $219.06 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 32.4%. EPS of $0.54 for the same period compares to $0.91 a year ago.

The reported revenue represents a surprise of +6.84% over the Zacks Consensus Estimate of $205.04 million. With the consensus EPS estimate being $0.54, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net product sales- Trokendi XR: $8.4 million compared to the $5.94 million average estimate based on two analysts. The reported number represents a change of -25% year over year.
• Revenues- Net product sales- Oxtellar XR: $8.8 million versus $5.37 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -24.1% change.
• Revenues- Net product sales- Qelbree: $89.2 million versus the two-analyst average estimate of $89.83 million. The reported number represents a year-over-year change of +15%.
• Revenues- Royalty, licensing and other revenues: $18 million versus the two-analyst average estimate of $2.5 million. The reported number represents a year-over-year change of +141.4%.
• Revenues- Net product sales- ONAPGO: $13.5 million versus $12.97 million estimated by two analysts on average.
• Revenues- Collaboration revenue (ZURZUVAE): $35.4 million compared to the $34.16 million average estimate based on two analysts.
• Revenues- Net product sales: $165.7 million versus $158.76 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.
• Revenues- Net product sales- GOCOVRI: $37.6 million versus $39.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.

View all Key Company Metrics for Supernus here>>>

Shares of Supernus have returned -7.1% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.